Discover 1,567 paid clinical trials in Jersey City, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,567
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
for
Relapsed/Refractory Acute Myeloid Leukemia
Location: Hackensack NJ, New Haven CT, Philadelphia PA,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT06714591
Phase1, Recruiting
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
for
Malignant Melanoma
Location: Hackensack NJ, Fairfax VA, Toronto, Brampton,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06961006
Phase2, Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
for
Advanced Lung Non-Small Cell Carcinoma,
Location: The Bronx NY, Stamford CT, Stony Brook NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 70+
Code: NCT06096844
Phase3, Recruiting
Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment
for
Prostate Cancer
Location: Hackensack NJ
Sponsor: Hackensack Meridian Health
Sex: Male
Age: 18+
Code: NCT07011342
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
for
Advanced Solid Tumors, Malignant Neoplasm
Location: Hackensack NJ, Richmond VA, Birmingham AL, Miami FL,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06818643
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Location: Hackensack NJ, New Brunswick NJ, Philadelphia PA,
Sponsor: CellCentric Ltd.
Sex: All
Age: 18+
Code: NCT07096778
Phase2, Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
for
Cervical Squamous Cell Carcinoma,
Location: Hackensack NJ, New Haven CT, Fairfax VA, Louisville KY,
Sponsor: Alentis Therapeutics AG
Sex: All
Age: 18+
Code: NCT07169734
Phase1, Phase2, Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
for
Squamous Cell Carcinoma of Head and Neck
Location: New Brunswick NJ, New Haven CT, Baltimore MD, Boston MA,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06385080
Phase1, Phase2, Recruiting
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
for
Metastatic Neoplasm
Location: Hackensack NJ, Chicago IL, Houston TX
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07030712
Phase1, Recruiting
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
for
Growth Hormone Deficiency
Location: New Hyde Park NY, Morristown NJ, Washington D.C. DC,
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
for
Allogeneic Stem Cell Transplant Recipient
Location: Hackensack NJ
Sponsor: Hackensack Meridian Health
Sex: All
Age: 18 - 65
Code: NCT07214688
Phase2, Recruiting
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
for
Locally Advanced or Metastatic Malignant Solid Tumors
Location: Hackensack NJ, New Hyde Park NY, Fairfax VA,
Sponsor: Astellas Pharma Global Development, Inc.
Sex: All
Age: 18+
Code: NCT07287995
Phase1, Phase2, Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
for
Hepatocellular Carcinoma (HCC)
Location: Hackensack NJ, Nashville TN, Portland OR
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07291076
Phase1, Phase2, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)